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UNAVOIDABLY UNSAFE PRODUCTS: CLARIFYING
THE MEANING AND POLICY BEHIND COMMENT K
VICTOR E. SCHWARTZ*
INTRODUCTION
It has been wisely said that words not placed in context are merely
pretext. This sage advice provides illumination for understanding and clari-
fying both the policy that underlies, and the meaning of, comment k of
Restatement (Second) of Torts, Section 402A-unavoidably unsafe prod-
ucts.' The context for the development of comment k was the formal birth
of strict products liability tort law. 2 Strict products liability theory emerged
in the early 1960's when the reporter of the Restatement of Torts, William
Prosser, and his council of advisors were attempting to synthesize a group
of cases that had permitted persons injured by products to recover damages
without having to prove that the manufacturer failed to use reasonable care.
A careful examination of the Appendix to Section 402A of the Restatement3
and discussions by the eminent Professor John W. Wade, 4 who later became
the reporter for the Restatement itself, show that all of the cases that were
considered involved mismanufactured products-contaminated food products
or products with construction defects. These were cases where products
contained foreign objects, were missing important parts, or were not assem-
bled in accordance with the manufacturer's own design plans. 5 Nevertheless,
when the language of Section 402A of the Restatement was drafted, it did
not use the phrase, "mismanufactured products." It simply spoke of prod-
ucts that were "in a defective condition unreasonably dangerous to the user
or consumer .... -6 Although the Restatement had addressed the issue of
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J. WADE, V. SCHWARTZ, CASES AND MATERIALS ON TORTS (7th ed. 1982); co-author, V.
SCHWARTZ, P. LEE, K. KELLY, MULTISTATE LITIGATION (1985 - Mathew Bender); author,
COMPARATIVE NEGLIGENCE (2d ed. 1985). Mr. Schwartz served as Chairman of the Federal
Interagency Task Force on Product Liability and was the principal author of the Uniform
Product Liability Act. He also has been a law professor at the University of Cincinnati College
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1. RESTATEMENT (SECOND) OF TORTS § 402A comment k (1965).
2. See RESTATEMENT (SECOND) OF TORTS § 402A comment a (1965).
3. RESTATEMENT (SECOND) OF TORTS, Appendix, Vol. 3 at 1 (1966).
4. See Wade, On the Nature of Strict Tort Liability for Products, 44 Miss. L. J. 825,
830-31 (1973).
5. See, e.g., Mazetti v. Armour & Co., 75 Wash. 622, 135 P. 633 (1913); Coca-Cola
Bottling Works v. Lyons, 145 Miss. 876, 111 So. 305 (1927).
6. RESTATEMENT (SECOND) OF TORTS § 402A (1965).
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liability for the design of products in an earlier section,7 specifically referred
to warnings in comment j of Section 402A, and made clear in both cases
that the liability basis was negligence, the generality in the language of 402A
created in the mind of the reporter a need to show with some specificity
what Section 402A did not cover. The American Law Institute's debates on
Section 402A make this absolutely clear.8 A description of the group of
products which the reporter did not wish to place under the rule of Section
402A were set forth in comment k-so called "unavoidably unsafe prod-
ucts." It is appropriate to begin with the description of those products from
the Restatement itself:
There are some products which, in the present state of human
knowledge, are quite incapable of being made safe for their intended
and ordinary use. These are especially common in the field of drugs.
An outstanding example is the vaccine for the Pasteur treatment of
rabies, which not uncommonly leads to very serious and damaging
consequences when it is injected. Since the disease itself invariably
leads to a dreadful death, both the marketing and use of the vaccine
are fully justified, notwithstanding the unavoidable high degree of
risk which they involve. Such a product, properly prepared, and
accompanied by proper direction and warning, is not defective, nor
is it unreasonably dangerous. The same is true of many other drugs,
vaccines, and the like, many of which for this very reason cannot
legally be sold except to physicians, or under the prescription of a
physician. It is also true of many new or experimental drugs as to
which, because of lack of time and opportunity for sufficient medical
experience, there can be no assurance of safety, or perhaps even the
purity of ingredients, but such experience as there is justifies the
marketing and use of the drug notwithstanding a medically recog-
nizable risk. The seller of such products, again with a qualification
that they are properly prepared and marketed, and proper warning
is given, when the situation calls for it, is not to be he held to strict
liability for unfortunate consequences attending their use, merely
because he has undertaken to supply the public with an apparently
useful and desirable product, attended with a known but apparently
reasonable risk.
Although learned scholars 9 have suggested that the words are obscure or
even meaningless, a careful consideration of these words demonstrates that
they have a definite meaning.
7. RESTATEMENT (SEcoND) OF TORTS § 398 (1965).
8. American Law Institute, 38th Annual Meetings, A.L.I. PROC. 87-88 (1962).
9. See Twerski, National Product Liability Legislation: In Search for the Best of all
Possible Worlds, 18 IDAHO L. REv. 411, 430 (1982); Page, Generic Product Risks: The Case
Against Comment k and For Strict Liability, 5 N.Y.U.L. REv. 853 (1983).
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More importantly the policy behind the words should be clear to both
lawyer and non-lawyer alike-maybe even clearer to the non-lawyer. In that
regard, unfortunately, an ingredient that sometimes creeps into the legal
profession is an overly technical reading of a document-so overly technical
that it misses the basic message. The basic message here is that, in general,
ethical drugs and harms that arise out of their use should not subject their
manufacturer, distributor or retailer to strict liability. Society wishes to
encourage the manufacture of ethical drugs, and the research and develop-
ment of new drugs. The imposition of strict liability would stifle these goals.
On the other hand, neither the letter of, nor policy underlying, the
comment gives carte blanche to pharmaceutical companies to manufacture
unreasonably unsafe products. If an ethical drug, in light of the state of
human knowledge at the time of manufacture, can be made safe for its
intended and ordinary use, the manufacturer is to meet that standard. If it
is not possible to meet this goal, the product still must be "properly
prepared"-mismanufactured products will not be tolerated, unless, in light
of the current knowledge it is impossible to guarantee "purity of ingredi-
ents." Perhaps more importantly, all pharmaceutical products have to be
accompanied by proper directions and warnings.' 0 This article will expand
upon this guideline later.
At this point, however, the policy underlying comment k should be clear:
it balances basic tort law considerations of deterrence, incentives of safety,
and compensation. The Restatement authors believed that classic negligence
law was adequate and sufficient to provide incentives for safety for the
design of ethical drugs and vaccines." They also believed that it was
inappropriate to impose tort law rules for compensation in this context.
While comment k could be read to apply to other products, it does not
really give us any examples or suggest other areas where the policy balancing
is precisely the same. For this reason, the courts and most commentators
have assumed that comment k relates to pharmaceuticals and this assumption
as a practical matter appears to be correct.'2 This article will discuss, briefly,
some areas where comment k has created uncertainty at least in the mind of
some courts and scholars. The article will utilize the basic policy goals that
underlie comment k to resolve these purported ambiguities with the hope
that this analysis will be of assistance to courts and others that must now
and in the future address these problems. The article does not intend to treat
comment k as revealed Gospel, but to indicate where and where not the
author believes the choices made under comment k are appropriate.
The areas focused on will include:
10. See, e.g., Reyes v. Wyeth Laboratories, 498 F.2d 1264, 1276 (5th Cir.), cert. denied,
419 U.S. 1096 (1974).
II. RESTATEMENT (SEcoND) OF TORTS § 402A comment k (1965).
12. See, e.g., Lindsay v. Ortho Pharmaceutical Corp., 637 F.2d 87 (2d Cir. 1980); Page,
supra note 9, at 853.
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(1) Does comment k include drugs that, over time, are shown not
to be efficacious?
(2) How does comment k treat known risks?
(3) Does comment k include products that contain risks that are
unknown at the time the product is manufactured, but manifest
themselves later?
(4) How does comment k relate to the duty to warn about risks?
(5) Decision-making under comment k: Who should resolve the key
questions?
1. Does Comment K Include Drugs that, Over
Time, Are Shown Not to Be Efficacious?
As most people know, before drugs are placed in the marketplace, they
must go through intensive testing by the Food and Drug Administration.'
On the average, it takes at least seven to ten years for a drug to receive
unconditional approval for marketing, with a physician's prescription, to the
general- public. A principal focus of the Food and Drug Administration,
apart from safety, is efficacy. Since every drug includes some risks, the Food
and Drug Administration regards efficacy as essential-if one is to take
risks, he or she should obtain the desired result.
There has been a suggestion in at least one case that comment k should
only apply to drugs that turn out to be efficacious.' 4 Nevertheless, nothing
in comment k states this, and, in fact, its underlying policy suggests the
opposite. Comment k notes that its policy applies in particular "to many
new or experimental drugs as to which, because of lack of time and
opportunity for sufficient medical experience, there can be no assurance of
safety, or perhaps even purity of ingredients, but such experience as there is
justifies the marketing and use of the drug notwithstanding a medically
recognizable risk. . . ."s I am not referring here to situations in which the
drug manufacturer withheld information from the Food and Drug Admin-
istration, engaged in fraud or negligent conduct. To the contrary, I am
13. Before new drugs may be sold, the Food and Drug Administration must approve a
New Drug Application (NDA) which shows that the drug is safe and effective. 21 U.S.C. § 355
(1972). NDA safety tests are conducted under detailed regulations. 21 C.F.R. § 312 (1985). See
generally, Virts and Weston, Expectations and the Allocation of Research and Development
Resources, in DRUGS AND HEALTH (R. Helms ed. 1981); R.W. Hansen, The Pharmaceutical
Development Process: Estimates of Development Costs and Times and the Effects of Proposed
Regulatory Changes, in IssuEs N PHARMACEUTICAL ECONOMICS (R. Chien ed.).
14. Ferrigno v. Eli Lilly & Co., 175 N.J. Super. 551, 556, 420 A.2d 1305, 1319 (Law Div.
1980), vacated on authority of Namm v. Charles E. Frosst & Co., 178 N.J. Super. 19, 427
A.2d 1121 (App. DN. 1981).
15. RESTATEMENT (SECOND) OF TORTS § 402A comment k (1965).
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referring here to the situation in which there has been reasonable care on
the part of the manufacturer, and presumably on the part of the Food and
Drug Administration, and where, at the time of manufacture, it was believed
that the drug would be efficacious. In that context, does the policy underlying
comment k suggest that we should hold the manufacturer strictly liable for
an adverse result? If the authors of the Restatement were willing to allow
drugs in the marketplace where there could not be a guarantee of "purity of
ingredients," one can reasonably conclude that they would permit the
marketing, without strict tort liability, of drugs that appeared to be effica-
cious. If there is further doubt about this matter, one should focus on the
closing words in comment k which exclude the application of strict liability
to "an apparently useful and desirable product .... "16 While the focus in
this sentence, again, is on the "risk" attendant to some products, the
execution would apply with equal fortitude to products that appeared from
all scientific testing by both the manufacturer and the Food and Drug
Administration to work and work well.
This result is in accord with sound social policy. Again, remember that
liability is not being barred where there has been fault. Rather, the concern
here is with cases in which drugs have been manufactured in accordance
with the highest standard of reasonable care. It is in society's interest to
encourage the marketing of drugs that will help eliminate the dreaded
scourges of mankind-cancer, liver and kidney ailments, heart disease. Do
we want, by hindsight, to impose absolute or strict liability where, in spite
of the best of intentions, learning and study, a drug did not fulfill the goal?
It is hard to think of a more certain way to stifle and discourage attempts
to cure.
2. How Does Comment K Treat Known Risks?
The first part of comment k, particularly the example of the Pasteur
treatment of rabies, discusses the exclusion of strict liability for drugs where,
at the time of marketing, it is crystal clear that the benefits of the drug
outweigh the risks. There could be no clearer example of situations encom-
passed by the comment than where, in the words of comment k, "the disease
itself invariably leads to a dreadful death ... and ingestion of or vaccination
with the pharmaceutical will prevent death. . . . "'7 It is clear that the
comment applies where lifesaving drugs contain risks of harmful side effects.
Many pharmaceuticals that have been in the marketplace for a long time,
such as penicillin, aureomyecin, or even ordinary aspirin, involve a similarly
easy to understand risk-benefit analysis with easy conclusions that the product
should be marketed in spite of risks that it might entail.
There are those who might argue that this is where the protection of
comment k should stop: in the case where it is crystal clear that the benefits
16. Id. (emphasis added).
17. Id.
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of a drug outweigh its risks. But that is not where comment k does stop.
Comment k also focuses on "many new or experimental drugs... where
there can be no assurance of safety. .."I' and where a risk-benefit analysis
shows that the product was "apparently useful and desirable. . ". ."19 More-
over, the comment includes products that are attended with a "known but
apparently reasonable risk."
'20
As the majority of the case law reflects, risk-benefit analysis must be
viewed at the time of marketing, not later. This is why in a case in which
the drug Chloroquine resulted in the loss of sight, the court held for the
defendant. 21 If comment k is confined to classic well-known drugs with clear
risk-utility results and the word "apparently" is left out, we lose the basic
public policy thrust that underlies comment k-to encourage the development
of new drugs that have the potential for conquering disease.
3. Does Comment K Include Products that Contain Risks that are
Unknown at the Time of Manufacture but Manifest Themselves Later?
It has been argued that comment k only covers risks that are known at
the time the product is marketed. 22 Comment k states, in part, that it
addresses products with a "known but apparently reasonable risk. ... 21
The comment was applied in a case involving the drug aralen, where the
drug appeared to have some risks affecting eyesight, but later turned out to
be much more serious and caused blindness. 24 What if there were no hint of
the risk involved at the time the drug was marketed?
Almost all courts have said comment k still applies. 25 The overall context
of the comment itself suggests that it should apply a fortiori. Again, comment
k excludes strict liability for drugs where "there can be no assurance of
safety .... ,,26 One might assume, in plain English, that "no" means "no."
While the unknown risk is something that we all dread, it is the very and
most worrisome factor that the Food and Drug Administration and phar-
maceutical manufacturers must guard against.
Applying comment k to drugs that contain risks that were unknown at
the time of manufacture simply keeps these drugs within the ambit of
negligence law. Under negligence law, the pharmaceutical company is held
18. Id.
19. Id. (emphasis added).
20. Id.
21. Cochran v. Brooke, 243 Or. 89, 409 P.2d 904 (1966).
22. See Twerski, supra note 9, at 430-31 n.54.
23. RESTATEMENT (SECOND) OF TORTS § 402A comment k (1965).
24. See Cochran v. Brooke, 243 Or. 89, 409 P.2d 904 (1966).
25. See, e.g., Ortho Pharmaceutical Corp. v. Chapman, 180 Ind. App. 33, 388 N.E.2d
541, 545 (Ind. Ct. App. 1979); Gaston v. Hunter, 121 Ariz. 33, 588 P.2d 326, 338 (Ariz. Ct.
App. 1978); Chambers v. G.D. Searle & Co., 441 F. Supp. 377, 380 (D. Md. 1975), aff'd, 567
F.2d 269 (4th Cir. 1977).
26. RESTATEMENT (SECOND) OF TORTS § 402A comment k (1965).
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to the very highest of standards. 27 The pharmaceutical company must act as
a reasonable person would have acted in the same or similar circumstances.
The circumstances in which pharmaceutical manufacturers must deal directly
involve severe risks to human life. Thus, their standard of care is not the
"reasonableness" of a person who repairs a television set or drives a car 28-
it is the most serious and intense obligation that one can find in the entire
body of negligence law. To go beyond this, and require manufacturers to be
responsible for the unknown (that is, to impose absolute or strict liability),
flies in the face of the overall policy underlying the section. The Supreme
Court of New Jersey, not known for comforting product manufacturer
defendants, appears to have recognized this fact. In addressing the case in
which a risk of harm was alleged to have been unknown at the time of
manufacture, the New Jersey Supreme Court indicated that it would not
impose liability for either the design, the drug, or the failure to warn about
the unknown risk. 29 Even in one of the few decisions that appeared to reject
comment k, Collins v. Eli Lilly Co.,30 the Supreme Court of Wisconsin
acknowledged that it: "[R]ecognized that in some exigent circumstances it
may be necessary to place a drug on the market before adequate testing can
be done... '"31
The issue at hand, however, is not whether comment k applies to drugs
containing risks that could have been known at the time of manufacture.
Rather, we are focusing here on situations in which the very best experience
and knowledge existing when the product was made indicated that the drug
was safe.
Finally, as a practical matter, there is little difference in the terms of
actual harm between a risk that was "apparently reasonable" and turned
out not to be (for example, risk of slight impairment of vision was known
but blindness resulted) and a totally unknowable risk. To differentiate
between the known risk that turns out to be more serious and a totally new
risk, which may indeed be a minor risk, does not square with the policy
underlying comment k or for that matter with common sense. The only
reasonable conclusion is that comment k includes products which contain
risks that were not knowable at the time of manufacture.
4. How Does Comment K Relate
to the Duty to Warn About Risks?
It is surprising that something that is clear from the text of the Restate-
ment has not always been regarded as such by courts or commentators:
27. See 21 U.S.C. § 355 (1972); 21 C.F.R. § 312 (1985).
28. See W. PROSSER, J. ,VADE, V. SCHWARTZ, CASES AND MATERIALS ON TORTS at 203
(7th Ed. 1982).
29. Feldman v. Lederle Laboratories, 97 N.J. 429, 479 A.2d 374 (1984).
30. Collins v. Eli Lilly Co., 116 Wis.2d 166, 342 N.W.2d 37, 52, cert. denied, 105 S. Ct.
107 (1984).
31. Id. at , 342 N.W.2d at 52.
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comment k deals with liability for design of, and not the warning about,
products. With one possible exception, dealing with a situation in which it
is virtually impossible to have "purity of ingredients," which could be called
a construction defect (and the focus probably was on blood transfusion cases
where, at the time, hepatitis virus could not be detected), it is design liability
that comment k speaks to.
When we are talking about drugs that are apparently useful and desirable
at the time of marketing, the policy underlying comment k would strongly
suggest that it would be inappropriate, at a later date, to impute knowledge
to the manufacturer and ask "whether a person having that knowledge would
have marketed the product.' '32 Nevertheless, the "black letter" of comment
k gives us only a rather non-descriptive word about what should be done
about warning. Comment k of Section 402A speaks to products "accom-
panied by proper directions and warning .... -3" But what is proper?
The Restatement itself, for all products, answers this question in com-
ment j to Section 402A. This, too, has been recognized by the Supreme
Court of New Jersey. 34 The manufacturer must warn about risks of which
he has knowledge or, by the application of reasonable, developed human
skill and foresight, he should have knowledge-the presence of the ingredient
and the danger.
35
Note that comment j talks about "human skill" not skill beyond what
prudent and reasonable human beings can achieve. In today's product
liability context, it is important to note that the word used is "foresight"
not hindsight. Obviously, it would have been clearer if comment k referred
to comment j, but the Restatement authors did not do this. They did the
next best thing, they put one comment next to the other.
As the Supreme Court of New Jersey has recognized: "[Als to warnings,
generally, conduct should be measured by knowledge at the time the manu-
facturer distributed the product."' 36 Did the defendant know, or should he
have known, of the danger, given the scientific, technological and other infor-
mation available when the product was distributed? Or, in other words, did
he have actual or constructive knowledge of the danger?
The court then went on to cite comment j. 37 All of this is in full accord
with the policy underlying comment k. But then, to adhere with what
appeared to be an obeisance to verbal semantics, the Supreme Court of New
Jersey has suggested that approaching things in this way would not be true
32. See Phillips v. Kimwood Machine Co., 269 Or. 485, 525 P.2d 1033, 1036-38 (1974);
Hayes v. Ariens Co., 391 Mass. 407, 462 N.E.2d 273, 277 (1984); see also WADE, supra note
4, at 834-37.
33. RESTATEMENT (SECOND) OF TORTS § 402A comment k (1965).
34. Feldman v. Lederle Laboratories, 97 N.J. 429, 479 A.2d 374, 386 (1984).





"strict liability." 3 8 So, to adhere to a label, the court put the burden of
proof on the defendant to show why it did not know of the risk. 9 Unfor-
tunately, this approach invites the trier of fact to do the very thing the
Restatement has cautioned to against: apply hindsight rather than foresight.
Also, as all persons who have argued cases in court know, it is extradordi-
narily difficult to prove a negative-that you did not know of a risk. The
myriad of cases where plaintiff's counsel has been able, by the preponderance
of evidence, to prove that manufacturers knew or should have known of a
risk are ample pragmatic evidence that the burden of proof should remain
on the plaintiff-discovery works. There is nothing in comment k or j that
suggests reversing the burden of proof and, hopefully, the Supreme Court
of New Jersey, as it ultimately did in Beshada v. Johns-Manville Products
Corp.40, will retreat from this untenable position and join the overwhelming
majority of courts and the Restatement: the burden of proof shall be on the
plaintiff.
Comment k and j as they apply to warnings can potentially give too
much protection to drug manufacturers because a black letter reading of the
two comments can suggest that obligations regarding liability are frozen in
time. After a drug has been manufactured, new knowledge can, under and
through the operation of reasonable prudence, come to the attention of a
drug manufacturer. New data and information about the pharmaceutical
continue to develop and come to light. The public policy of encouraging the
production of new and hopefully efficacious drugs is not compromised by
imposing a reasonable standard on manufacturers to be responsible for new
developments and risks in drugs they have marketed. Again, this is not
found in the black letter text of comment k, but it is in accord with tort law
and its policy of balancing compensation and incentives for safety. The
Uniform Product Liability Act 4' contains such an obligation as does recent
legislation proposed in the United States Congress. 42
5. Decision-Making Under Comment K:
Who Should Resolve the Key Questions?
One ambiguity that has risen under comment k is much more procedural
than substantive-who should decide the key questions that underlie comment
k, the judge or jury? As this article has empirically demonstrated, the basic
issues underlying comment k are not questions of what occurred at a
particular time or of who did what to whom. To the contrary, they are
questions of law and policy. Does comment k include drugs that, over time,
38. Id.
39. Id. at......_, 479 A.2d at 388.
40. 90 N.J. 191, 447 A.2d 539 (1982).
41. Model Uniform Product Liability Act § I04(B)(6), 44 Fed. Reg. 62721 (Oct. 31, 1979).
42. See S. 100, 99th Cong., Ist Sess., 131 CONG. REc. 5218 (daily ed., Jan. 3, 1985)
(Product Liability Act).
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are shown not be efficacious? How does comment k treat known risks? Does
comment k include products that contain risks that are unknown at the time
the product is manufactured but manifest themselves later? How does
comment k relate to the duty to warn about risks? All of these questions are
matters of interpretation of law and the application of policy. They are
particularly suited for discussion, analysis and resolution by a court.
In that regard, a court can consider both hearsay and non-hearsay
evidence. The court can take judicial notice of the debates by the American
Law Institute, practices of the Food and Drug Administration, law review
articles and other scholarship. With due respect for the powers of a jury to
go back in time and understand and draw opinions about events that have
occurred in the past, the jury is not in a position to resolve the questions
that stream around comment k. It is the responsibility of the judicial branch
and, hopefully, it will be carried out wisely.
CONCLUSION
While some scholars and courts recently have suggested that comment k
is obscure or even inappropriate, it has served the law well over the past 20
years. While no legal document is free from ambiguity, and this is certainly
the case with comment k, many of the problems in this area are more
apparent than real. As this article has pointed out, many of the so-called
ambiguities can be answered in the language of the comment itself. When
doubt enters into the picture, the underlying policy of comment k can provide
the answer. The policy of encouraging innovation in the drug field would
seem to be one that should not wither with time but should be encouraged
now and in the future. This was seen even in the time of initial exploration
and perhaps overfondness for strict product liability-by the authors of the
Restatement themselves.
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